Overview
Publication Venue For
Clinical Diagnostic Testing for Human Cytomegalovirus Infections.
221:S74-S85.
2020
Cytomegalovirus Genetic Diversity Following Primary Infection.
221:715-720.
2020
RSV Antivirals: Problems and Progress.
2020
High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.
221:218-222.
2020
HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients.
220:1620-1628.
2019
An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis.
220:1399-1405.
2019
Pneumococci Can Become Virulent by Acquiring a New Capsule From Oral Streptococci.
2019
Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results from the META Longitudinal Cohort Study.
220:1172-1177.
2019
Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults with Incident HIV-1 Infection.
220:432-441.
2019
Rapid boosting of HIV-1 neutralizing antibody responses in humans following a prolonged immunologic rest period.
219:1755-1765.
2019
Tenofovir gel for prevention of herpes simplex virus type 2 acquisition: Findings from the VOICE trial.
219:1940-1947.
2019
Remembering the host in tuberculosis drug development.
219:1518-1524.
2019
Blood Viral Load in Symptomatic Congenital Cytomegalovirus Infection.
219:1398-1406.
2019
Food Insecurity Is Associated With Inflammation Among Women Living With HIV.
219:429-436.
2019
In Silico and Experimental Evaluation of Primer Sets for Species-Level Resolution of the Vaginal Microbiota Using 16S Ribosomal RNA Gene Sequencing.
219:305-314.
2019
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies..
218:1954-1963.
2018
Influence of Immune Priming and Egg Adaptation in the Vaccine on Antibody Responses to Circulating A(H1N1)pdm09 Viruses after Influenza Vaccination in Adults.
218:1571-1581.
2018
Seroconversion for Cytomegalovirus Infection during Pregnancy and Fetal Infection in a Highly Seropositive Population: "the BraCHS Study".
218:1200-1204.
2018
Identification of Key Bacteria Involved in the Induction of Incident Bacterial Vaginosis: A Prospective Study.
218:966-978.
2018
Contribution of Breastfeeding to False-Positive Saliva Polymerase Chain Reaction for Newborn Congenital Cytomegalovirus Screening.
217:1612-1615.
2018
Kinetics of Serological Responses in Critically Ill Patients Hospitalized with 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009-2011.
217:1078-1088.
2018
Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex virus-2, on viral shedding and lesions: Results of a randomized placebo-controlled trial.
218:1890-1899.
2018
Breast milk human cytomegalovirus (CMV) viral load and the establishment of breast milk CMV-pp65-Specific CD8 T Cells in Human CMV infected mothers.
216:1176-1179.
2017
Epstein-Barr Virus Type 2 Infects T Cells in Healthy Kenyan Children.
216:670-677.
2017
In Memorium: William Ernest Dismukes 1939-2017.
2017
New Horizons in Mycoplasma genitalium Treatment.
216:S412-S419.
2017
Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy.
216:82-91.
2017
Lower Levels of Cervicovaginal Tryptophan Are Associated with Natural Clearance of Chlamydia in Women.
215:1888-1892.
2017
Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy.
215:1725-1733.
2017
Immunoglobulin-based investigation of spontaneous resolution of chlamydia trachomatis infection.
215:1653-1656.
2017
Therapeutic vaccine for Genital herpes simplex virus-2 infection: Findings from a randomized trial.
215:856-864.
2017
TURQUOISE-I part 1b: Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 coinfected patients on darunavir.
215:599-605.
2017
Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men.
215:1352-1361.
2017
Cross-reactive antibody responses to novel h5nx influenza viruses following homologous and heterologous prime-boost vaccination with a prepandemic stockpiled a(h5n1) vaccine in humans.
216:S555-S559.
2017
Diversity in the US Infectious Diseases Workforce: Challenges for Women and Underrepresented Minorities.
216:S606-S610.
2017
Effect of priming with seasonal influenza a(h3n2) virus on the prevalence of cross-reactive hemagglutination-inhibition antibodies to swine-origin a(h3n2) variants.
216:S539-S547.
2017
Mild respiratory illness among young children caused by highly pathogenic avian influenza a (h5n1) virus infection in Dhaka, Bangladesh, 2011.
216:S520-S528.
2017
Pathogenesis of Non-Zika Congenital Viral Infections.
216:S912-S918.
2017
Sunday in the Park with Infectious Disease: Workforce Mismatch in a Colorful Universe of Possibilities.
216:S581-S587.
2017
Intra-amniotic ureaplasma parvum-induced maternal and fetal inflammation and immune responses in rhesus macaques.
214:1597-1604.
2016
Seasonal influenza vaccination of children induces humoral and cell-mediated immunity beyond the current season: Cross-reactivity with past and future strains.
214:1477-1486.
2016
Influenza vaccination and antiviral therapy in pregnant women.
214:505-506.
2016
More Easily Cultivated Than Identified: Classical Isolation with Molecular Identification of Vaginal Bacteria.
214:S21-S28.
2016
Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses.
214:S1-S5.
2016
The Vaginal Microbiome: Current Understanding and Future Directions.
214:S36-S41.
2016
Periodic Presumptive Treatment for Vaginal Infections May Reduce the Incidence of Sexually Transmitted Bacterial Infections.
213:1932-1937.
2016
Uropathogenic Escherichia coli engages CD14-dependent signaling to enable bladder-macrophage-dependent control of acute urinary tract infection.
213:659-668.
2016
Vaccination with heterologous HIV-1 envelope sequences and heterologous adenovirus vectors increases T-cell responses to conserved regions: HVTN 083.
213:541-550.
2016
Incidence and predictors of abnormal anal cytology findings among HIV-infected adults receiving contemporary antiretroviral therapy.
213:351-360.
2016
Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study.
213:335-342.
2016
Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza.
213:1180-1188.
2016
Breast Milk as a Potential Source of Epstein-Barr Virus Transmission Among Infants Living in a Malaria-Endemic Region of Kenya.
212:1735-1742.
2015
A murine viral outgrowth assay to detect residual HIV type 1 in patients with undetectable viral loads.
212:1387-1396.
2015
The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2.
212:S204-S209.
2015
Randomized trial of periodic presumptive treatment with high-dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women.
211:1875-1882.
2015
Challenges and opportunities in developing respiratory syncytial virus therapeutics.
211:S1-S20.
2015
A newly emerged swine-origin influenza a(H3N2) variant dampens host antiviral immunity but induces potent inflammasome activation.
212:1923-1929.
2015
Antibody to influenza virus neuraminidase: An independent correlate of protection.
212:1191-1199.
2015
Oral and vaginal tenofovir for genital herpes simplex virus type 2 shedding in immunocompetent women: A double-blind, randomized, cross-over trial.
212:1949-1956.
2015
Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosis.
212:793-802.
2015
Safer conception strategies for HIV-serodiscordant couples: How safe is safe enough?.
212:1525-1528.
2015
Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: A conceptual model.
210:338-343.
2014
Basophil expansion protects against invasive pneumococcal disease in mice.
210:14-24.
2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia ankara vaccines expressing HIV-1 virus-like particles.
210:99-110.
2014
The scarlet H.
209:315-317.
2014
Aging promotes b-1b cell responses to native, but not protein-conjugated, pneumococcal polysaccharides: Implications for vaccine protection in older adults.
209:87-97.
2014
Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens.
210:1415-1418.
2014
HIV-1 infection of macrophages dysregulates innate immune responses to mycobacterium tuberculosis by inhibition of interleukin-10.
209:1055-1065.
2014
Low invasiveness of pneumococcal serotype 11A is linked to ficolin-2 recognition of O-acetylated capsule epitopes and lectin complement pathway activation.
210:1155-1165.
2014
Organ pathology in the absence of bacteria?.
209:971.
2014
Reply to hickey and forney.
210:1683-1684.
2014
Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans.
209:986-994.
2014
Transplacental transfer of azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate model.
209:898-904.
2014
Changes in measles serostatus among HIV-infected zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities.
208:1747-1755.
2013
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observation.
208:1391-1396.
2013
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals.
208:1240-1249.
2013
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
208:884-891.
2013
Heterozygosity for the F508del mutation in the cystic fibrosis transmembrane conductance regulator anion channel attenuates influenza severity.
208:780-789.
2013
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
208:662-671.
2013
Spontaneous resolution of genital chlamydia trachomatis infection in women and protection from reinfection.
207:1850-1856.
2013
Inducible nitric oxide contributes to viral pathogenesis following highly pathogenic influenza virus infection in mice.
207:1576-1584.
2013
Vaginal biofilms and bacterial vaginosis: Of mice and women.
207:1481-1483.
2013
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.
207:709-720.
2013
Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia ankara as a smallpox vaccine in HIV-infected subjects.
207:749-758.
2013
Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice.
207:501-510.
2013
Immunoglobulin-specific responses to chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection.
206:1836-1843.
2012
Mucosal escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial.
206:1931-1935.
2012
Oseltamivir dosing in premature infants.
206:847-850.
2012
Protecting adults from influenza: Tis the season to learn from the pandemic.
206:803-805.
2012
Chlamydia trachomatis, mycoplasma genitalium, and trichomonas vaginalis infections in men with nongonococcal urethritis: Predictors and persistence after therapy.
206:357-365.
2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
206:431-441.
2012
HLA-B signal peptide polymorphism influences the rate of HIV-1 acquisition but not viral load.
205:1797-1805.
2012
Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis.
205:1580-1588.
2012
Tuberculosis and HIV control in sub-saharan african prisons: "thinking outside the prison cell".
205.
2012
Sometimes, more is better.
205:697-699.
2012
Local innate immune responses and influenza virus transmission and virulence in ferrets.
205:474-485.
2012
Reply to Ganesan et al.
205:518-519.
2012
Use of a human influenza challenge model to assess person-to-person transmission: Proof-of-concept study.
205:35-43.
2012
A pre-pandemic outbreak of triple-reassortant swine influenza virus infection among university students, South Dakota, 2008.
204:1165-1171.
2011
Mixed infection and strain diversity in congenital cytomegalovirus infection.
204:1003-1007.
2011
Expression of innate and adaptive immune mediators in human corneal tissue infected with Aspergillus or fusarium..
204:942-950.
2011
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: Implications for tuberculosis screening.
204:893-901.
2011
Establishing and sustaining a healthy vaginal environment: Analysis of data from a randomized trial of periodic presumptive treatment for vaginal infections.
204:323-326.
2011
Increasing clarity on bone loss associated with antiretroviral initiation.
203:1705-1707.
2011
Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.
203:1534-1541.
2011
Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe.
203:1182-1191.
2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
203:610-619.
2011
Divergent mechanisms for passive pneumococcal resistance to β-Lactam antibiotics in the presence of Haemophilus influenzae.
203:549-555.
2011
Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples.
203:487-495.
2011
Control of varicella disease, version 2.0.
203:297-298.
2011
Infection with highly pathogenic H7 influenza viruses results in an attenuated proinflammatory cytokine and chemokine response early after infection.
203:40-48.
2011
Bacterial vaginosis assessed by Gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection.
202:1907-1915.
2010
Cytomegalovirus viruria and DNAemia in healthy seropositive women.
202:1800-1803.
2010
Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States.
202:1567-1576.
2010
Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus.
202:1161-1170.
2010
Coinfection with Haemophilus influenzae promotes pneumococcal biofilm formation during experimental otitis media and impedes the progression of pneumococcal disease.
202:1068-1075.
2010
Reply to Tarchini.
202:979.
2010
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group study.
202:717-722.
2010
Oseltamivir dosing for influenza infection in premature neonates.
202:563-566.
2010
A new pneumococcal serotype, 11E, has a variably inactivated wcjE Gene.
202:29-38.
2010
Duration of untreated, uncomplicated chlamydia trachomatis genital infection and factors associated with chlamydia resolution: A review of human studies.
201.
2010
A Phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.
201:1729-1735.
2010
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
201:1481-1487.
2010
Of ferrets and humans: Influenza pathogenesis.
201:976-977.
2010
Group B Streptococcus (GBS) urinary tract infection involves binding of GBS to bladder uroepithelium and potent but GBS-specific induction of interleukin 1α.
201:866-870.
2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
201:803-813.
2010
An evolving understanding of genital herpes pathogenesis: Is it time for our approach to therapy to change as well?.
201:486-487.
2010
Cytomegalovirus reinfections in healthy seroimmune women.
201:386-389.
2010
Repeated Chlamydia trachomatis genital infections in adolescent women.
201:42-51.
2010
A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vetnam/1203/2004, in Mice.
200:1874-1883.
2009
Bacterial vaginosis: Are we coming full circle?.
200:1633-1635.
2009
Role played by psrP-secY2A2 (accessory region 34) in the invasive disease potential of streptococcus pneumoniae.
200:1180-1181.
2009
Age-associated inflammation and Toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia.
200:546-554.
2009
Risk factors associated with subclinical human infection with avian influenza a (H5N1) virus-cambodia, 2006.
199:1744-1752.
2009
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
199:1638-1647.
2009
Reply to Zhang.
199:1250-1251.
2009
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans.
199:872-880.
2009
Streptococcus pneumoniae forms surface-attached communities in the middle ear of experimentally infected chinchillas.
199:786-794.
2009
Distribution of genital Lactobacillus strains shared by female sex partners.
199:680-683.
2009
Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine.
199:320-325.
2009
Differential effects of pneumococcal vaccines against serotypes 6A and 6C.
198:1818-1822.
2008
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
198:1345-1352.
2008
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia.
198:1019-1027.
2008
Antibodies against PsrP, a novel Streptococcus pneumoniae adhesin, block adhesion and protect mice against pneumococcal challenge.
198:375-383.
2008
A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.
197:1185-1188.
2008
Efavirenz-Based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
197:1006-1010.
2008
Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.
197:836-845.
2008
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
197:867-870.
2008
Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women.
197:548-554.
2008
Lack of evidence of avian-to-human transmission of avian influenza A (H5N1) virus among poultry workers, Kano, Nigeria, 2006.
196:1685-1691.
2007
Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media.
196:1528-1536.
2007
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza h5N1 virus infection.
196:1493-1499.
2007
The association between Trichomonas vaginalis infection and level of vaginal lactobacilli, in nonpregnant women.
196:1102-1107.
2007
Selective testing criteria for gonorrhea among young women screened for chlamydial infection: Contribution of race and geographic prevalence.
196:731-737.
2007
HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages.
195:1373-1380.
2007
Correlates of sexually transmitted infections in young women [1].
195:303.
2007
Functionally competent antigen-specific Cd127hi memory CD8 + T cells are preserved only in HIV-infected individuals receiving early treatment.
195:108-117.
2007
Haplotypes of IL6 and IL10 and susceptibility to human T lymphotropic virus type I infection among children.
194:1565-1569.
2006
Prevalence of primary HIV-1 drug resistance among recently infected adolescents: A Multicenter Adolescent Medicine Trials Network for HIV/AIDS Interventions Study.
194:1505-1509.
2006
Reply to Forney et al. [4].
194:1469-1470.
2006
Reply to Lawn and Wood [2].
194:1468.
2006
Lessons learned from reconstructing the 1918 influenza pandemic.
194.
2006
Prevention and treatment of influenza in high-risk groups: Children, pregnant women, immunocompromised hosts, and nursing home residents.
194.
2006
Seasonal and pandemic influenza preparedness: A global threat.
194.
2006
Seasonal and pandemic influenza: Recommendations for preparedness in the United States.
194.
2006
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: The results of AIDS Clinical Trials Group 5068.
194:623-632.
2006
Time to translate new knowledge into practice: A call for a national genital herpes control program.
194:6-7.
2006
A persistent(ly) enigmatic ecological mystery: Bacterial vaginosis.
193:1475-1477.
2006
Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy.
193:1437-1440.
2006
Host immunogenetics and control of human herpesvirus-8 infection.
193:1054-1062.
2006
The spectrum of genital herpes simplex virus infection in men attending a sexually transmitted disease clinic.
193:905-911.
2006
Risk factors for cervicitis among women with bacterial vaginosis.
193:617-624.
2006
Local and systemic cytokine levels in relation to changes in vaginal flora.
193:556-562.
2006
Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection.
193:16-26.
2006
Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women.
192:2039-2044.
2005
Trichomoniasis in adolescents: A marker for the lack of a public health response to the epidemic of sexually transmitted diseases in the United States.
192:2036-2038.
2005
Association between human leukocyte antigen class II alleles and genotype of Borrelia burgdorferi in patients with early Lyme disease.
192:2020-2026.
2005
Association between genital tract cytomegalovirus infection and bacterial vaginosis.
192:1727-1730.
2005
Abnormal vaginal flora as a biological risk factor for acquisition of HIV infection and sexually transmitted diseases.
192:1315-1317.
2005
Molecular epidemiology of foodborne hepatitis A outbreaks in the United States, 2003.
192:1323-1330.
2005
A case-control study to examine HLA haplotype associations in patients with posttreatment chronic lyme disease.
192:1010-1013.
2005
High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
192:1249-1259.
2005
Treatment of intestinal helminths does not reduce plasma concentrations of HIV-1 RNA in coinfected Zambian adults.
192:1277-1283.
2005
Virulence in mice of pneumococcal clonal types with known invasive disease potential in humans.
192:791-800.
2005
Changing dynamics of varicella-zoster virus infections in the 21st century: The impact of vaccination.
191:1999-2001.
2005
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy.
191:1210-1215.
2005
Human leukocyte antigen and cytokine gene variants as predictors of recurrent Chlamydia trachomatis infection in high-risk adolescents.
191:1084-1092.
2005
Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system.
191:227-233.
2005
Influence of host genetic variation on susceptibility to HIV type 1 infection.
191.
2005
Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA Loads.
190:1970-1978.
2004
Epidemiological and genetic correlates of incident Chlamydia trachomatis infection in North American adolescents.
190:1723-1729.
2004
Tissue-specific contributions of pneumococcal virulence factors to pathogenesis.
190:1661-1669.
2004
Commentary: Ch'ien LT, Cannon NJ, Charamella LJ, et al. Effect of adenine arabinoside on severe herpesvirus hominis infections in man: Preliminary report. J Infect Dis 1973; 128:658-63.
190:1360-1367.
2004
Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen.
190:928-934.
2004
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants.
190:975-978.
2004
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.
190:886-893.
2004
Recombinant interferon-γ1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.
189:2185-2191.
2004
Activation of porcine cytomegalovirus, but not porcine lymphotropic herpesvirus, in pig-to-baboon xenotransplantation.
189:1628-1633.
2004
HLA-DRB1 and -DQB1 alleles and haplotypes in Zambian couples and their associations with heterosexual transmission of HIV type 1.
189:1696-1704.
2004
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
189:1221-1231.
2004
Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation.
189:2037-2046.
2004
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359.
189:1176-1184.
2004
Effect of adenine arabinoside on severe Herpesvirus hominis infections in man. 1973..
190:1362-1367.
2004
Influence of human leukocyte antigen-B22 alleles on the course of human immunodeficiency virus type 1 infection in 3 cohorts of white men.
188:856-863.
2003
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
188:625-634.
2003
High rates of Trichomonas vaginalis among men attending a sexually transmitted diseases clinic: Implications for screening and urethritis management.
188:465-468.
2003
Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae.
188:339-348.
2003
Long‐Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters.
188:388-396.
2003
Heritability analysis of cytokines as intermediate phenotypes of tuberculosis.
187:1679-1685.
2003
Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection.
187:1264-1271.
2003
Immunogenic protein contaminants in pneumococcal vaccines.
187:1019-1023.
2003
Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients.
187:901-908.
2003
Cytomegalovirus production by infected astrocytes correlates with transforming growth factor-β release.
187:534-541.
2003
Antigen burden is a major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: Potential implications for therapeutic immunization.
187:364-374.
2003
A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced ige antibodies.
186:1261-1269.
2002
Durability of response to treatment among antiretroviral-experienced subjects: 48-Week results from AIDS Clinical Trials Group Protocol 359.
186:626-633.
2002
Role of bacteriophage MAV1 as a mycoplasmal virulence factor for the development of arthritis in mice and rats.
186:432-435.
2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (aids clinical trials group study 850).
186:198-204.
2002
Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings..
185:1818-1821.
2002
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women.
185:1307-1313.
2002
Human cytomegalovirus enhances chemokine production by lipopolysaccharide-stimulated lamina propria macrophages.
185:584-590.
2002
Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure.
185:428-438.
2002
Human cytomegalovirus primes lamina propria macrophages for enhanced LPS-stimulated chemokine production.
185:584-90.
2002
Pilot Study of the Effects of Intermittent Interleukin‐2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection.
185:61-8.
2002
Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998.
185:1005-1010.
2002
Growth inhibition of Candida albicans by human vaginal epithelial cells.
184:1489-1493.
2001
Quantitative culture of Chlamydia trachomatis: Relationship of inclusion-forming units produced in culture to clinical manifestations and acute inflammation in urogenital disease.
184:1350-1354.
2001
Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: A multicenter, seroepidemiology study.
184:1022-1028.
2001
Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs..
183:1547-1553.
2001
Polar production of interleukin-8 by mesothelial cells promotes the transmesothelial migration of neutrophils: Role of intercellular adhesion molecule-1.
183:1638-1645.
2001
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
183:1688-1693.
2001
Clones of Streptococcus pneumoniae isolated from nasopharyngeal carriage and invasive disease in young children in central Tennessee.
183:1501-1507.
2001
Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy.
183:1522-1525.
2001
Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with RGP120.
183:563-570.
2001
Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes.
183:368-376.
2001
Onchocerciasis in a nonendemic population: Clinical and immunologic assessment before treatment and at the time of presumed cure.
183:512-516.
2001
Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.
183:401-408.
2001
Epidemiology and clinical manifestations of unique Chlamydia trachomatis isolates that occupy nonfusogenic inclusions.
184:879-884.
2001
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS clinical trials group protocol 373.
183:715-721.
2001
Enterotoxin adjuvants have direct effects on T cells and antigen- presenting cells that result in either interleukin-4-dependent or - independent immune responses.
182:180-190.
2000
Induction of acute pleural inflammation by Staphylococcus aureus. I. Cd4+ T cells play a critical role in experimental empyema.
181:1693-1699.
2000
A foodborne outbreak of gastroenteritis associated with Norwalk-like viruses: First molecular traceback to deli sandwiches contaminated during preparation.
181:1467-1470.
2000
Inflammatory cytokine mRNA expression during early and persistent Helicobacter pylori infection in nonhuman primates.
181:783-786.
2000
Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong.
181:344-348.
2000
Growth inhibition of Candida by human oral epithelia cells.
182:1479-1485.
2000
Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.
182:1694-1701.
2000
Lamina propria lymphocytes, not macrophages, express CCR5 and CXCR4 and are the likely target cell for human immunodeficiency virus type 1 in the intestinal mucosa.
182:785-791.
2000
Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media.
182:1146-1152.
2000
Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts.
180:1763-1770.
1999
Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.
180:1851-1862.
1999
A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
180:970-975.
1999
Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997.
180:505-508.
1999
Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men.
180:299-309.
1999
Correlation of behaviors with microbiological changes in vaginal flora.
180:1632-1636.
1999
Human interleukin-12 enhances interferon-γ-producing influenza-specific memory CD8+ cytotoxic T lymphocytes.
180:1477-1486.
1999
Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants.
180:1569-1576.
1999
Mycobacterium-induced transmesothelial migration of monocytes into pleural space: Role of intercellular adhesion molecule-1 in tuberculous pleurisy.
180:1616-1623.
1999
Involvement of matrix metalloproteinases in human immunodeficiency virus type 1-induced replication by clinical Mycobacterium avium isolates..
180:1142-1152.
1999
Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features.
180:702-707.
1999
Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.
180:847-849.
1999
Differential susceptibility of two species of macaques to experimental vaginal candidiasis.
180:802-810.
1999
Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity.
180:122-132.
1999
Mucosal Th1- versus Th2-type responses for antibody- or cell-mediated immunity to simian immunodeficiency virus in rhesus macaques.
179.
1999
Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection.
179.
1999
Mucosal immune system of the human genital tract.
179.
1999
Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons.
179:449-454.
1999
Molecular characterization of a globally distributed lineage of serotype 12F Streptococcus pneumoniae causing invasive disease.
179:414-422.
1999
Herpes zoster: Risk categories for persistent pain.
179:9-15.
1999
HIV-1 Infection, mucosal immunity and pathogenesis: Comments and conference summary.
179:397-400.
1999
Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities.
178:1795-1798.
1998
Genital human papillomavirus infection in women who have sex with women.
178:1604-1609.
1998
Identification of T cells that respond to serovar-specific regions of the Chlamydia trachomatis major outer membrane protein in persons with serovar E infection.
178:1713-1718.
1998
Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure.
178:1767-1775.
1998
Mycobacterium-mediated chemokine expression in pleural mesothelial cells: role of C-C chemokines in tuberculous pleurisy..
178:1450-1456.
1998
Use of statistics and scientific inference: Odds ratios, likelihood ratio, and receiving operating characteristic curves [2] (multiple letters).
178:921-923.
1998
Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection.
177:790-792.
1998
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: A meta-analysis of randomized individual patient data.
178:349-359.
1998
Cytokine and antibody responses in women infected with Neisseria gonorrhoeae: Effects of concomitant infections.
178:742-751.
1998
Erratum: Retraction: A rabbit model for human cytomegalovirus-induced chorioretinal disease (The Journal of Infectious Diseases (1998) 177 (1778)).
178:601.
1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1(MN) gp120, HIV-1(SF2) recombinant gp120, or both vaccines in seronegative adults.
177:1230-1246.
1998
Induction of Th2 cytokine expression for p27-specific IgA B cell responses after targeted lymph node immunization with simian immunodeficiency virus antigens in rhesus macaques.
177:26-33.
1998
Recombinant helicobactev pylori urease activates primary mucosal macrophages.
178:1516-1520.
1998
Retraction: A rabbit model for human cytomeglovirus--induced chorioretinal disease (J Infect Dis 1993;168:336-44)..
177:1778.
1998
The identification of risk factors associated with persistent pain following herpes zoster.
178.
1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.
177:40-47.
1998
Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group..
175:1080-1086.
1997
A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis.
176:227-232.
1997
Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine.
175:352-363.
1997
Age-related decline in murine macrophage production of nitric oxide.
175:1004-1007.
1997
Alterations to the cell wall of Histoplasma capsulatum yeasts during infection of macrophases or epithelial cells.
175:1538-1544.
1997
Antimicrobial resistance in Neisseria genorrhoeae in the United States, 1988-1994: The emergence of decreased susceptibility to the fluoroquinolones.
175:1396-1403.
1997
Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: Results of a phase II study.
175:1080-1086.
1997
High incidence of Kaposi's sarcoma-associated herpesvirus and Epstein- Barr virus in tumor lesions and peripheral blood mononuclear cells from patients with Kaposi's sarcoma in Uganda.
175:947-950.
1997
Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae.
176:698-703.
1997
Intranasal immunization of mice with PspA (Pneumococcal surface protein A) can prevent lntranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.
175:839-846.
1997
DNA polymorphisms and variant penicillin-binding proteins as evidence that relatively penicillin-resistant pneumococci in Western Canada are clonally related.
174:884-888.
1996
Pneumococcal vaccine response in human immunodeficiency virus-infected patients.
173:777-778.
1996
A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides.
173:113-118.
1996
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease.
174:1162-1167.
1996
Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection [4].
174:673.
1996
Effects of influenza A nucleoprotein on polymorphonuclear neutrophil function.
173:279-284.
1996
Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia.
174:141-156.
1996
Immunoregulation in onchocerciasis: Persons with ocular inflammatory disease produce a Th2-like response to Onchocerca volvulus antigen.
174:380-386.
1996
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.
173:627-635.
1996
Synthesis of tumor necrosis factor-α mRNA in bronchoalveolar lavage cells from human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia.
174:654-659.
1996
The presence or absence of active infection, not clinical status, is most closely associated with cytokine responses in lymphatic filariasis.
173:1453-1459.
1996
The repertoire of human antibodies to the carbohydrate capsule of Streptococcus pneumoniae 6B.
174:75-82.
1996
Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice.
173:380-386.
1996
Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group..
171:857-863.
1995
A randomized, double-blind, placebo-controlled trial of systemically administered interferon-α, -β, or -γ in combination with cryotherapy for the treatment of condyloma acuminatum.
171:1081-1089.
1995
Abnormal lymphatic function in presymptomatic bancroftian filariasis.
171:997-1001.
1995
Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection.
171:1115-1121.
1995
Detection of herpesvirus dna by nested polymerase chain reaction in cerebrospinal fluid of human immunodeficiency virus-infected persons with neurologic disease: A prospective evaluation.
172:1087-1090.
1995
Diagnosis of herpes simplex encephalitis: Application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease.
171:857-863.
1995
Modulation of human immunodeficiency virus type 1 infection of human monocytes by iga.
172:855-858.
1995
Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary cmv infection in the guinea pig model.
172:1212-1220.
1995
Virus-specific antibody responses to human cytomegalovirus (hcmv) in human immunodeficiency virus type 1-infected persons with hcmv retinitis.
171:182-185.
1995
Association of hepatitis c virus infection with false-positive tests for syphilis.
170:1579-1581.
1994
Characterization of mucosal antibodies in persons with AIDS.
170:299-307.
1994
Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases.
169:990-995.
1994
Intestinal mucosal immunoglobulins during human immunodeficiency virus type 1 infection.
170:299-307.
1994
Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis.
170:927-933.
1994
Prevalence and epidemiologic correlates of human t cell lymphotropic virus infection among intravenous drug users.
169:962-967.
1994
Truly infection-free persons are rare in areas hyperendemic for african onchocerciasis.
170:1054-1055.
1994
A Rabbit Model for Human Cytomegalovirus-Induced Chorioretinal Disease.
168:336-344.
1993
Antibodies Induced by a Primary Cytomegalovirus Infection React with Human Herpesvirus 6 Proteins.
168:1119-1126.
1993
Cytoadherence of plasmodium falciparum-infected erythrocytes to microvascular endothelium is regulatable by cytokines and phorbol ester.
167:698-703.
1993
Esophageal disease in AIDS is associated with pathologic processes rather than mucosal human immunodeficiency virus type 1.
167:547-552.
1993
Oral immunization with influenza virus in biodegradable microspheres.
167:84-90.
1993
Parvovirus Bl9-specific DNA in bone marrow from B19 arthropathy patients: Evidence for B19 virus persistence.
167:744-748.
1993
Penile Intraepithelial Neoplasia: Clinical Presentation and an Analysis of the Physical State of Human Papillomavirus DNA.
168:38-46.
1993
Transmission of Chlamydia trachomatis among Sex Partners Assessed by Polymerase Chain Reaction.
168:488-492.
1993
Virus-specific antibody responses in mothers and their newborn infants with asymptomatic congenital cytomegalovirus infections.
167:72-77.
1993
Workshop on In Vitro Neutralization of Chlamydia trachomatis: Summary of Proceedings.
168:415-420.
1993
Evidence for a Clonal Origin of Relative Penicillin Resistance among Type 9L Pneumococci in Northwestern Canada.
165:671-675.
1992
Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group..
165:450-455.
1992
Association of Biologic False-Positive Reactions for Syphilis with Human Immunodeficiency Virus Infection.
165:1124-1126.
1992
Characterization of the Human IgG Antibody VLRepertoire to Haemophilus influenzae Type b Polysaccharide.
165:S53-S56.
1992
Disseminated Herpes Zoster in the Immunocompromised Host: A Comparative Trial of Acyclovir and Vidarabine.
165:450-455.
1992
Evolution of the Human Immunodeficiency Virus Epidemic among Patients Attending Sexually Transmitted Disease Clinics: A Decade of Experience.
165:541-544.
1992
Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals.
165:251-255.
1992
Infection with human t lymphotropic virus types i and ii in sexually transmitted disease clinics in Baltimore and New Orleans.
165:920-924.
1992
Therapeutic Approaches to Varicella-Zoster Virus Infections.
166:S51-S57.
1992
An experimental model of early central nervous system syphilis.
163:825-829.
1991
Epidemiologic studies of group 9 pneumococci in terms of protein type and 9N versus 9V capsular type.
163:812-818.
1991
Evaluation of a test based on baculovirus-expressed glycoprotein G for detection of herpes simplex virus type-specific antibodies.
164:1196-1199.
1991
Herpes simplex encephalitis: The case against brain biopsy [1].
164:426-427.
1991
High-level viremia in adults and children infected with human immunodeficiency virus: Relation to disease stage and cd4+lymphocyte levels.
164:72-80.
1991
Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected adults.
164:973-975.
1991
Sexually transmitted diseases in a population of intravenous drug users: Association with seropositivity to the human immunodeficiency virus (hiv).
164:457-463.
1991
Use of brain biopsy for diagnostic evaluation of patients with suspected herpes simplex encephalitis: A statistical model and its clinical implications.
163:17-22.
1991
Use of brain biopsy for diagnostic evaluation of patients with suspected herpes simplex encephalitis: a statistical model and its clinical implications. NIAID Collaborative Antiviral Study Group..
163:17-22.
1991
Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics..
162:1309-1315.
1990
Bactericidal and opsonic activity of IgGl and IgG2 anticapsular antibodies to Haemophilus influenzae type b.
162:163-171.
1990
Behavioral contributions to acquisition of gonorrhea in patients attending an inner city sexually transmitted disease clinic.
161:938-941.
1990
Candida albicans in patients with the acquired immunodeficiency syndrome: Absence of a novel or hypervirulent strain.
162:513-518.
1990
Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for candida albicans.
161:999-1005.
1990
In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys Aotus trivirgatus.
162:313-321.
1990
Scedosporium inflatum: Clinical spectrum of a newly recognized pathogen.
161:102-107.
1990
Treatment of condyloma acuminatum with three different interferon-α preparations administered parenterally: A double-blind, placebocontrolled trial.
162:1270-1276.
1990
Determinants Of Emergence Of Antibiotic-Resistant Neisseria Gonorrhoeae.
159:900-907.
1989
Efficacy of Inactivated Influenza a Virus (H3N2) Vaccines Grown in Mammalian Cells or Embryonated Eggs.
160:191-198.
1989
Host and bacterial factors associated with haemophilus influenzae type b disease in minnesota children vaccinated with type b polysaccharide vaccine.
159:908-916.
1989
Syphilis and HIV Infection.
160:530-534.
1989
The Efficacy of Ivermectin in the Chemotherapy of Gastrointestinal Helminthiasis in Humans.
159:1151-1153.
1989
Primary cytomegalovirus infection in pregnancy: comparison of antibody responses to virus-encoded proteins between women with and without intrauterine infection..
158:917-924.
1988
Acute antibody responses to giardia lamblia are depressed in patients with aids.
157:798-804.
1988
Antibody response of the newborn after herpes simplex virus infection.
158:925-933.
1988
Antibody to herpes simplex virus (Hsv) icp-35 proteins after hsv challenge of animals immunized with hsv subunit vaccines.
157:1178-1186.
1988
Ceftriaxone therapy for incubating and early syphilis.
158:881-884.
1988
Changing patterns of herpes simplex virus infection in neonates.
158:109-116.
1988
Eggs of schistosoma mansoni stimulate endothelial cell proliferation in vitro.
158:556-562.
1988
The acquired immunodeficiency syndrome (AIDS) and infection with the human immunodeficiency virus (HIV).
158:273-285.
1988
Antibody Response to Herpes Simplex Virus Glycoprotein d: Effects of Acyclovir and Relation to Recurrence.
156:423-429.
1987
Antibody response to virus-encoded proteins after cytomegalovirus mononucleosis.
156:615-621.
1987
Detection of Antibodies to Herpes Simplex Virus in the Cerebrospinal Fluid of Patients with Herpes Simplex Encephalitis.
155:38-44.
1987
Detection of antigen to herpes simplex virus in cerebrospinal fluid from patients with herpes simplex encephalitis.
155:1172-1178.
1987
Estimated Prevalence of Ocular Toxoplasmosis and Toxocariasis in Alabama.
156:414.
1987
Naturally occurring antibodies to phosphocholine as a potential index of antibody responsiveness to polysaccharides.
155:1307-1314.
1987
A rabbit model of focal herpes simplex encephalitis.
153:732-735.
1986
Natural and vaccine-related immunity to streptococcus pneumoniae.
154:245-256.
1986
Antigens of treponema pallidum recognized by igg and igm antibodies during syphilis in humans.
151:264-272.
1985
Disproportionate expansion of a minor t cell subset in patients with lymphadenopathy syndrome and acquired immunodeficiency syndrome.
151:555-559.
1985
Reply.
151:971.
1985
The hla complex and the pathogenesis of infectious diseases.
151:1-8.
1985
Infections caused by herpes simplex virus in the immunocompromised host: Natural history and topical acyclovir therapy.
150:323-329.
1984
Vidarabine therapy for mucocutaneous herpes simplex virus infections in the immunocompromised host.
149:1-8.
1984
Rapid diagnosis of pneumonia due to cytomegalovirus with specific monoclonal antibodies..
147:1119-1120.
1983
Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus.
148:953-961.
1983
Herpes simplex virus encephalitis: Laboratory evaluations and their diagnostic significance.
145:829-836.
1982
Cytomegalovirus infection in patients with renal transplants: Potentiation by antithymocyte globulin and an incompatible graft.
142:9-17.
1980
The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin.
141:55-63.
1980
Identification of patients with increased risk of infection with herpes simplex virus after renal transplantation.
140:487-492.
1979
Productive infection with cytomegalovirus and herpes simplex virus in renal transplant recipients: Role of source of kidney.
137:556-563.
1978
Treatment of infections due to Herpesvirus in humans: a critical review of the state of the art..
133 Suppl:A101-A108.
1976
Adenine Arabinoside for Therapy of Herpes Zoster in Immunosuppressed Patients: Preliminary Results of a Collaborative Study.
133:A184-A191.
1976
Effect of adenine arabinoside on cytomegalovirus infections.
130:32-39.
1974
Effect of adenine arabinoside on severe herpesvirus hominis infections in man.
128:658-663.
1973
Inhibition of growth of candida albicans by iron-unsaturated lactoferrin: Relation to host-defense mechanisms in chronic mucocutaneous candidiasis.
124:539-544.
1971
